CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
4.560
0.00 (0.00%)
At close: Apr 2, 2026, 4:00 PM EDT
4.520
-0.040 (-0.88%)
After-hours: Apr 2, 2026, 4:34 PM EDT
CytomX Therapeutics Revenue
In the year 2025, CytomX Therapeutics had annual revenue of $76.20M, down -44.82%. CytomX Therapeutics had revenue of $663.00K in the quarter ending December 31, 2025, a decrease of -98.26%.
Revenue (ttm)
$76.20M
Revenue Growth
-44.82%
P/S Ratio
12.77
Revenue / Employee
$1,104,362
Employees
69
Market Cap
985.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 76.20M | -61.90M | -44.82% |
| Dec 31, 2024 | 138.10M | 36.89M | 36.45% |
| Dec 31, 2023 | 101.21M | 48.05M | 90.38% |
| Dec 31, 2022 | 53.16M | 15.85M | 42.48% |
| Dec 31, 2021 | 37.31M | -31.12M | -45.47% |
| Dec 31, 2020 | 68.43M | 41.53M | 154.36% |
| Dec 31, 2019 | 26.90M | -32.60M | -54.79% |
| Dec 31, 2018 | 59.50M | -12.12M | -16.92% |
| Dec 31, 2017 | 71.62M | 58.78M | 457.59% |
| Dec 31, 2016 | 12.85M | 6.90M | 116.21% |
| Dec 31, 2015 | 5.94M | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | 888.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xeris Biopharma Holdings | 291.85M |
| Geron | 183.88M |
| Xencor | 125.58M |
| UroGen Pharma | 109.79M |
| KalVista Pharmaceuticals | 73.62M |
| uniQure | 16.10M |
| Inventiva | 9.31M |
| Aktis Oncology | 6.50M |
CTMX News
- 15 days ago - Why Is CytomX Therapeutics Stock Falling On Wednesday? - Benzinga
- 15 days ago - CytomX Therapeutics: Great News, But Early Data Do Not Quite Justify This Price Level - Seeking Alpha
- 15 days ago - CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 17 days ago - CytomX Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 17 days ago - CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade) - Seeking Alpha
- 17 days ago - Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally - Benzinga
- 17 days ago - CytomX Therapeutics, Inc. (CTMX) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 17 days ago - CytomX Therapeutics Announces 2025 Financial Results and Provides Business Update - GlobeNewsWire